๐๐ฅ๐จ๐๐๐ฅ ๐๐ฌ๐ญ๐๐จ๐ง๐๐๐ซ๐จ๐ฌ๐ข๐ฌ ๐๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐๐๐ซ๐ค๐๐ญ
Osteonecrosis is a disease in which the bone cells collapse due to lack of blood flow in the bones. It is also known as avascular necrosis, aseptic necrosis or ischemic necrosis. Osteonecrosis is most commonly developed in hip bone (femur) or knees, while less often in shoulder, wrist, ankle, hands, and feet. It can cause mild to severe pain and may lead to micro-fracture. Osteonecrosis can be diagnosed by using X-ray, CT scan, MRI, bone scan, and functional bone tests. Osteonecrosis treatment targets symptoms and reduces pain via medication or surgery in extreme cases. According to the National Organization for Rare Disorders, osteonecrosis is one of the rare diseases, where less than 1 in 2000 are only affected by this disorder. In 2017, Bone Therapeutics reported that around 170,000 patients were suffering from osteonecrosis in Europe, the U.S., and Japan. The advancements in treatment technologies and gene therapy and stem cell-based osteonecrosis treatment are expected to propel growth of the global osteonecrosis treatment market during the forecast period.
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐จ๐ซ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐ญ โhttps://www.coherentmarketinsights.com/insight/request-sample/1490
๐๐ฅ๐จ๐๐๐ฅ ๐๐ฌ๐ญ๐๐จ๐ง๐๐๐ซ๐จ๐ฌ๐ข๐ฌ ๐๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐๐๐ซ๐ค๐๐ญ ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค
Advanced Therapy Medicinal Products (ATMPs) are a class of innovative therapies that comprise gene therapy, somatic cell therapy, and tissue-engineered products, and their introduction into the market is expected to drive the global osteonecrosis treatment market development. Osteonecrosis usually affects young population and this significantly will contributes towards growth of osteonecrosis treatment market. For instance, according to the American College of Rheumatology, in 2017, around 10,000 to 20,000 people in the U.S. who suffered from osteonecrosis were between the ages of 20 and 50. Currently, the osteonecrosis non-surgical treatment (medication) is symptomatic treatment that targets the symptoms and try to cure the disease. Hence, emerging players in the field of bone disease treatment is gaining momentum by introducing gene regulation approach. The key market players like Enzo Biochem, Inc. and Bone Therapeutics are aiming gene regulation and cell-based product treatment, which is expected to augment growth of osteonecrosis treatment market. For instance, PREOB manufactured by Bone Therapeutics, a cell-based medicinal product derived from autologous bone marrow stem cells, has been approved in the U.S., and is currently in the third phase of development in Europe.
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐๐ซ๐ ๐๐๐ ๐๐ซ๐จ๐๐ก๐ฎ๐ซ๐ @ย https://www.coherentmarketinsights.com/insight/request-pdf/1490
Although osteonecrosis is a rare disease, the global osteonecrosis treatment market is expected to grow tremendously, due to the burgeoning prevalence of causative agents for osteonecrosis. Side effects of various medicines taken during cancer, HIV/AIDS, osteoarthritis, osteoporosis or blood disorders or medical treatment such as chemotherapy, radiation therapy, high-dosage of steroids or organ transplants may increases the chances of having osteonecrosis. Furthermore, a few interventions such as Stanford Universityโs sponsored project aims at evaluation of osteonecrosis before and after decompression surgery with ferumoxytol-enhanced MRI, which improve detection and allow to track transplanted bone marrow cells. This intervention is in phase IV clinical trial and is expected to complete the project over the forecast period, which in turn, would propel the growth of the global osteonecrosis treatment market.
๐๐๐ ๐ข๐จ๐ง๐๐ฅ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ
North America is expected to hold a dominant position in the global osteonecrosis treatment market over the forecast period, due to increasing prevalence pool of osteonecrosis, and FDA approvals for new treatment options in the region. According to the 2015 NCBI report, it is estimated that around 20,000 to 30,000 new patients are diagnosed with osteonecrosis in the U.S. annually. Furthermore, the Asia Pacific market is expected to grow at a comparatively faster rate in the global osteonecrosis treatment market over the forecast period, owing to the increasing developmental activities carried out by various key players in this region. For instance, Bone Therapeutics and Asahi Kasei Corporation signed a license agreement in 2017 for the development and commercialization of PREOB in Japan.
๐๐ฅ๐จ๐๐๐ฅ ๐๐ฌ๐ญ๐๐จ๐ง๐๐๐ซ๐จ๐ฌ๐ข๐ฌ ๐๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐๐๐ซ๐ค๐๐ญ โ ๐๐๐ฒ ๐๐จ๐ฆ๐ฉ๐๐ญ๐ข๐ญ๐จ๐ซ๐ฌ
The major players involved in the global osteonecrosis treatment market include Bone Therapeutics, Enzo Biochem Inc., K-Stemcell Co. Ltd. Hospitals, and numerous leading universities and institutes.
๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐ญ๐ก๐ข๐ฌ ๐๐ซ๐๐ฆ๐ข๐ฎ๐ฆ ๐๐๐ฉ๐จ๐ซ๐ญ โย https://www.coherentmarketinsights.com/insight/buy-now/1490
๐๐จ๐ง๐ญ๐๐๐ญ ๐๐:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: [email protected]
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837